Pharmaxis Ltd (AU:SNT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Syntara Limited, a clinical stage drug development company listed on the ASX, is set to update investors in an upcoming webinar, highlighting its promising pipeline including the lead candidate SNT-5505 for myelofibrosis. The company is advancing several phase 2 studies in high unmet need areas, while also collaborating on treatments for neurodegenerative diseases and fibrosis. With a strong focus on innovation, Syntara aims to make significant strides in treating complex conditions.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.